Artificial neural networks and prostate cancer—tools for diagnosis and management
暂无分享,去创建一个
Kurt Miller | Klaus Jung | Henning Cammann | Carsten Stephan | H. Cammann | C. Stephan | K. Jung | K. Miller | H. Meyer | Xinhai Hu | Hellmuth-A. Meyer | Xinhai Hu | Hellmuth‐Alexander Meyer
[1] R. Autorino,et al. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. , 2012, Clinica chimica acta; international journal of clinical chemistry.
[2] G Bartsch,et al. The problem of cutoff levels in a screened population , 2001, Cancer.
[3] M. Meves,et al. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and Gleason score to predict positive surgical margins. , 2004, Urology.
[4] H. Cammann,et al. Artificial neural network (ANN) velocity better identifies benign prostatic hyperplasia but not prostate cancer compared with PSA velocity , 2008, BMC urology.
[5] C. Baird,et al. The pilot study. , 2000, Orthopedic nursing.
[6] U. Capitanio,et al. Predictive models before and after radical prostatectomy , 2010, The Prostate.
[7] M. Stöckle,et al. Artificial neural network analysis (ANNA) of prostatic transrectal ultrasound , 1999, The Prostate.
[8] Vassilis Poulakis,et al. Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen, and Gleason score to predict prostate cancer recurrence after radical prostatectomy. , 2004, European urology.
[9] H. Cammann,et al. External Validation of an Artificial Neural Network and Two Nomograms for Prostate Cancer Detection , 2012, ISRN urology.
[10] A W Partin,et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. , 1998, JAMA.
[11] Vassilis Poulakis,et al. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and gleason score for predicting prostate cancer biochemical recurrence after radical prostatectomy. , 2004, Urology.
[12] G Reibnegger,et al. Artificial Neural Networks in Laboratory Medicine and Medical Outcome Prediction , 1999, Clinical chemistry and laboratory medicine.
[13] S. Varambally,et al. 297 FEASIBILITY AND CLINICAL UTILITY OF A TMPRSS2:ERG GENE FUSION URINE TEST , 2009 .
[14] W. Pitts,et al. The statistical organization of nervous activity. , 1948, Biometrics.
[15] Dietmar Schnorr,et al. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. , 2006, Clinical chemistry.
[16] Shiro Baba,et al. Artificial neural network analysis for predicting pathological stage of clinically localized prostate cancer in the Japanese population. , 2002, Japanese journal of clinical oncology.
[17] P. Scardino,et al. Pathologic basis of the sonographic appearance of the normal and malignant prostate. , 1989, The Urologic clinics of North America.
[18] M. Roobol,et al. The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer , 2008, The Prostate.
[19] Sung Il Hwang,et al. Role of Transrectal Ultrasonography in the Prediction of Prostate Cancer , 2006, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.
[20] A. Jemal,et al. International variation in prostate cancer incidence and mortality rates. , 2012, European urology.
[21] Daniel Durkin,et al. A Critical Analysis Of The Literature In The Carroll College Library In The Field Of Economics With Recommendations , 1964 .
[22] H. Cammann,et al. A [‐2]proPSA‐based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases , 2009, The Prostate.
[23] S. Loening,et al. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia , 1997, Cancer.
[24] F. Montorsi,et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. , 2011, European urology.
[25] H. Lilja,et al. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. , 1987, The Journal of clinical investigation.
[26] Tapabrata Maiti,et al. Bayesian neural networks for bivariate binary data: an application to prostate cancer study , 2005, Statistics in medicine.
[27] Cristina Garibaldi,et al. Use of machine learning methods for prediction of acute toxicity in organs at risk following prostate radiotherapy. , 2011, Medical physics.
[28] Mesut Remzi,et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. , 2008, European urology.
[29] Yu-Chuan Li,et al. Artificial Neural Network to Predict Skeletal Metastasis in Patients with Prostate Cancer , 2009, Journal of Medical Systems.
[30] Freddie C Hamdy,et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. , 2005, European urology.
[31] Pierre I Karakiewicz,et al. Initial biopsy outcome prediction--head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. , 2007, European urology.
[32] H. Cammann,et al. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network. , 2009, Urology.
[33] Guido Schwarzer,et al. Artificial neural networks for diagnosis and prognosis in prostate cancer. , 2002, Seminars in urologic oncology.
[34] F. Lee,et al. Transrectal ultrasound in the diagnosis of prostate cancer: Location, echogenicity, histopathology, and staging , 1986, The Prostate.
[35] J. Affeldt,et al. The feasibility study , 2019, The Information System Consultant’s Handbook.
[36] Mesut Remzi,et al. Artificial neural networks for decision-making in urologic oncology. , 2003, Reviews in urology.
[37] A W Partin,et al. Artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer. , 2001, Urology.
[38] Shahrokh F. Shariat,et al. Inventory of prostate cancer predictive tools , 2008, Current opinion in urology.
[39] H. Klocker,et al. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. , 2003, The Journal of urology.
[40] 鮫島 浩,et al. Population-based study からみた神経予後不良因子の検討 , 2009 .
[41] P. Snow,et al. Introduction to artificial neural networks for physicians: Taking the lid off the black box , 2001, The Prostate.
[42] E. Capaldi,et al. The organization of behavior. , 1992, Journal of applied behavior analysis.
[43] H. Cammann,et al. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. , 2013, Clinical chemistry.
[44] Kazutaka Saito,et al. Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy. , 2008, European urology.
[45] Lucila Ohno-Machado,et al. Logistic regression and artificial neural network classification models: a methodology review , 2002, J. Biomed. Informatics.
[46] H. Cammann,et al. Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer. , 2013, Clinical chemistry.
[47] M. Kattan,et al. The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review. , 2008, European urology.
[48] K. Jung,et al. Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid. , 2011, European urology.
[49] E D Crawford,et al. Use of artificial neural networks in the clinical staging of prostate cancer: implications for prostate brachytherapy. , 2000, Techniques in urology.
[50] J. Schalken,et al. IMPROVED PREDICTION OF PROSTATE BIOPSY OUTCOME USING PCA3, TMPRSS2:ERG GENE FUSIONS AND SERUM PSA , 2008 .
[51] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[52] F ROSENBLATT,et al. The perceptron: a probabilistic model for information storage and organization in the brain. , 1958, Psychological review.
[53] Dietmar Schnorr,et al. An artificial neural network considerably improves the diagnostic power of percent free prostate‐specific antigen in prostate cancer diagnosis: Results of a 5‐year investigation , 2002, International journal of cancer.
[54] Klaus Jung,et al. A (-5, -7) proPSA based artificial neural network to detect prostate cancer. , 2006, European urology.
[55] A. Partin,et al. Evaluation of artificial neural networks for the prediction of pathologic stage in prostate carcinoma , 2001, Cancer.
[56] H. Cammann,et al. Three new serum markers for prostate cancer detection within a percent free PSA‐based artificial neural network , 2006, The Prostate.
[57] L. Kiemeney,et al. DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer , 2003 .
[58] H. Cammann,et al. Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network , 2006, Biological chemistry.
[59] A W Partin,et al. A neural network predicts progression for men with gleason score 3+4 versus 4+3 tumors after radical prostatectomy. , 2000, Urology.
[60] Z. Hall. Cancer , 1906, The Hospital.
[61] John A. W. McCall,et al. Machine learning for improved pathological staging of prostate cancer: A performance comparison on a range of classifiers , 2012, Artif. Intell. Medicine.
[62] P Finne,et al. Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. , 2000, Urology.
[63] Mesut Remzi,et al. An artificial neural network to predict the outcome of repeat prostate biopsies. , 2003, Urology.
[64] R W Veltri,et al. Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. , 1999, Urology.
[65] G. Sanz,et al. The use of neural networks and logistic regression analysis for predicting pathological stage in men undergoing radical prostatectomy: a population based study. , 2001, The Journal of urology.
[66] Anssi Auvinen,et al. Algorithms based on prostate‐specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false‐postitive PSA results in prostate cancer screening , 2004, International journal of cancer.
[67] Y. Yamada,et al. ACR Appropriateness Criteria® external-beam radiation therapy treatment planning for clinically localized prostate cancer. , 2012, Journal of the American College of Radiology : JACR.
[68] R. Meijer,et al. The value of an artificial neural network in the decision-making for prostate biopsies , 2009, World Journal of Urology.
[69] E. Crawford,et al. Impact of different variables on the outcome of patients with clinically confined prostate carcinoma: prediction of pathologic stage and biochemical failure using an artificial neural network. , 2001, Cancer.
[70] H. Cammann,et al. Comparison of two different artificial neural networks for prostate biopsy indication in two different patient populations. , 2007, Urology.
[71] Robert W Veltri,et al. Comparison of logistic regression and neural net modeling for prediction of prostate cancer pathologic stage. , 2002, Clinical chemistry.
[72] J Alfred Witjes,et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. , 2003, European urology.
[73] D. Chan,et al. [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. , 2007, The Journal of urology.
[74] G. Lockwood,et al. Predicting prostate biopsy outcome: artificial neural networks and polychotomous regression are equivalent models , 2011, International Urology and Nephrology.
[75] W. Catalona,et al. Artificial neural networks in the diagnosis and prognosis of prostate cancer: a pilot study. , 1994, The Journal of urology.
[76] D. E. Neal,et al. Neural network analysis of combined conventional and experimental prognostic markers in prostate cancer: a pilot study. , 1998, British Journal of Cancer.
[77] E J Gamito,et al. Genetic adaptive neural network to predict biochemical failure after radical prostatectomy: a multi-institutional study. , 2001, Molecular urology.
[78] S. Varambally,et al. FEASIBILITY AND CLINICAL UTILITY OF A TMPRSS2:ERG GENE FUSION URINE TEST , 2009 .
[79] A. Ronco,et al. Improving ultrasonographic diagnosis of prostate cancer with neural networks. , 1999, Ultrasound in medicine & biology.
[80] Andrew J. Vickers,et al. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring , 2008, Nature Reviews Cancer.
[81] A. Roli. Artificial Neural Networks , 2012, Lecture Notes in Computer Science.
[82] H. Klocker,et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. , 2010, European urology.
[83] Pierre I Karakiewicz,et al. An updated catalog of prostate cancer predictive tools , 2008, Cancer.
[84] S. Webb,et al. Use of artificial neural networks to predict biological outcomes for patients receiving radical radiotherapy of the prostate. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[85] Ulf Isacsson,et al. The effectiveness of artificial neural networks in evaluating treatment plans for patients requiring external beam radiotherapy. , 2004, Oncology reports.
[86] K. Yoshimura,et al. The use of artificial neural network analysis to improve the predictive accuracy of prostate biopsy in the Japanese population. , 2004, Japanese journal of clinical oncology.
[87] Klaus Jung,et al. Avoiding pitfalls in applying prediction models, as illustrated by the example of prostate cancer diagnosis. , 2011, Clinical chemistry.
[88] D. Wells,et al. A medical expert system approach using artificial neural networks for standardized treatment planning. , 1998, International journal of radiation oncology, biology, physics.
[89] A Errejon,et al. Artificial neural network model to predict biochemical failure after radical prostatectomy. , 2001, Molecular urology.
[90] Klaus Jung,et al. Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. , 2002, Clinical chemistry.
[91] K. Johnson. An Update. , 1984, Journal of food protection.
[92] A. Tewari,et al. Novel staging tool for localized prostate cancer: a pilot study using genetic adaptive neural networks. , 1998, The Journal of urology.
[93] A. H. Piray,et al. A comparison of artificial neural networks with other statistical approaches , 2010 .
[94] Peter Bartel,et al. Outcome prediction for prostate cancer detection rate with artificial neural network (ANN) in daily routine. , 2012, Urologic oncology.
[95] W. Ellis,et al. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. , 2009, European urology.
[96] Z. Zhang,et al. Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/mL. , 2000, Urology.
[97] H. Cammann,et al. An artificial neural network for five different assay systems of prostate‐specific antigen in prostate cancer diagnostics , 2008, BJU international.
[98] Shahrokh F. Shariat,et al. Comparison of Nomograms With Other Methods for Predicting Outcomes in Prostate Cancer: A Critical Analysis of the Literature , 2008, Clinical Cancer Research.
[99] Mattfeldt,et al. Prediction of prostatic cancer progression after radical prostatectomy using artificial neural networks: a feasibility study , 1999, BJU international.
[100] Mesut Remzi,et al. An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml. or less. , 2003, The Journal of urology.
[101] H. Cammann,et al. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection , 2005, BJU international.
[102] H. Cammann,et al. Internal validation of an artificial neural network for prostate biopsy outcome , 2010, International journal of urology : official journal of the Japanese Urological Association.
[103] A. Cestari,et al. Development and internal validation of a Prostate Health Index based nomogram for predicting prostate cancer at extended biopsy. , 2012, The Journal of urology.
[104] E. Crawford,et al. Combining artificial neural networks and transrectal ultrasound in the diagnosis of prostate cancer. , 2003, Oncology.
[105] M. Kenward,et al. An Introduction to the Bootstrap , 2007 .
[106] A. Partin,et al. Preoperative characteristics of high‐Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy , 2012, BJU international.
[107] A. Partin,et al. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. , 1994, The Journal of urology.
[108] Robin J Leach,et al. Predicting prostate cancer risk through incorporation of prostate cancer gene 3. , 2008, The Journal of urology.
[109] Nallasivam Palanisamy,et al. Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA , 2011, Science Translational Medicine.
[110] C. Catalano,et al. Conventional imaging and multiparametric magnetic resonance (MRI, MRS, DWI, MRP) in the diagnosis of prostate cancer. , 2012, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[111] T. Mattfeldt,et al. Prediction of Postoperative Prostatic Cancer Stage on the Basis of Systematic Biopsies using Two Types of Artificial Neural Networks , 2001, European Urology.